It explained why health care in the U.S. isn't working and hasn't worked for me in important ways. I now rely more on my sense of my health and do my own research. Generally, ask for a second opinion when I don't feel comfortable with the first.
The inside story of how Big Pharma’s relentless pursuit of ever-higher profits corrupts medical knowledge—misleading doctors, misdirecting American health care, and harming our health.
The United States spends an excess $1.5 trillion annually on health care compared to other wealthy countries—yet the amount of time that Americans live in good health ranks a lowly 68th in the world. At the heart of the problem is Big Pharma, which funds most clinical trials and therefore controls the research agenda, withholds the real data from those trials as corporate secrets, and shapes most of the information relied upon by health care professionals.…
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
This account of the early years of Vertex Pharmaceuticals, from its inception as a scrappy start-up to its early work in HIV, is a must-read classic for anyone interested in how science turns into new drugs. Barry Werth’s journalistic play-by-play is a cinematic, true-to-life picture of the strategic decisions, real-world challenges, and larger-than-life personalities that underlie modern drug development. His riveting follow-up, The Antidote, continues the saga by taking readers through Vertex’s pathbreaking work to transform the care of patients with hepatitis C and cystic fibrosis.
This is a poignant story of a quarrel that tore a family apart, but there is a wider message here. The elephant in the room is a care industry that has less to do with providing care for society’s most vulnerable members and more to do with maximizing profits for the pharmaceutical industry.
Freeing Teresa is a true story about an activist who tries to stop her powerful siblings from putting their disabled sister into a nursing home. She fails. And then must rescue her sister.
Franke James immediately objected when she heard her siblings’ plan to put their youngest sister, Teresa Heartchild, into a nursing home. “What about Teresa’s human rights?” But Franke was told that Teresa, who has Down syndrome, had lost her right to decide. She had been declared “not capable” by a social worker. The other siblings, now acting as Teresa’s “guardians,” insisted they had all the decision-making power,…
I have been a writer for thirty years and a horse lover my entire life. When I decided to write There Must Be Horses, I set out to learn about natural horsemanship and the way horses and people relate to each other. Of course, I then needed to try out all those exciting ideas myself so I bought myself a horse to help with my research. That was my excuse anyway – in truth I was finally fulfilling my childhood dream of a pony of my own. I still have that horse and would never part with him. He’s an important part of our family.
One of the main characters of this novel is a horse whisperer whose traumatic experiences on his eighth birthday have left him unable to speak. When he hears about stallions who are kept entirely indoors in order to produce a new drug, he sets out to ease their suffering. In the process, he meets Karen Lawford, the workaholic heir to the drug company, and tries to reawaken her love for horses so she can see that what is happening to the stallions is wrong, and tries to help her too. I love this well-crafted story of love and healing, but feel I should mention that it includes horses dying and being badly treated.
Outback horseman Lane Dimity is one of the most powerful social media personalities on the planet. Although unable to speak since the tragedy that took place on his eighth birthday, his words reach out across the world, changing lives. When he learns that more than a thousand stallions have been bred by the U.S. pharmaceutical company Pilatos, he is determined to free them. The heir to Pilatos, Karen Lawford, will do everything in her power to stop him.
Pilatos has gambled its future on the revolutionary drug Stablex, and the genetically unique stallions are needed to produce it...and there are…
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
A key issue about drug pricing not covered in Kolchinsky's book relates to value: even if a new therapy is affordable, is it "worth it"? Health economist Peter Neumann and his colleagues have written an authoritative, insightful, and extremely accessible history of efforts to align drugs' prices with their benefits to patients and society. This is a must-read guide for both insiders and non-experts to a topic that will be at the forefront of the drug pricing debate in the coming decade.
The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only…
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
I found, as a history buff, The Struggle for Drug Reform to be an eye-opener about how America’s exceptionally high drug prices among other deficits in health care quality and coverage resulted from the past exercise of power by the pharmaceutical industry, the lynchpin of America’s “medico-industrial complex.”
I was impressed by historian Tobbell’s meticulously researched account of the industry’s strategic alliances with self-interested medical scientists, not just conservative political forces, and its use of anti-communist propaganda to fight off the threat of drug pricing regulations.
I personally found important her discussions of how the industry allied with the American Medical Association against universal health care, against FDA demands for evidence about drug efficacy and safety before allowing drugs on the market, and against the threat to its profits from generic drugs.
Since the 1950s, the American pharmaceutical industry has been heavily criticized for its profit levels, the high cost of prescription drugs, drug safety problems, and more, yet it has, together with the medical profession, staunchly and successfully opposed regulation. "Pills, Power, and Policy" offers a lucid history of how the American drug industry and key sectors of the medical profession came to be allies against pharmaceutical reform. It details the political strategies they have used to influence public opinion, shape legislative reform, and define the regulatory environment of prescription drugs. Untangling the complex relationships between drug companies, physicians, and academic…
As a published author, Debra’s passion for fast-paced, unputdownable novels is unquenchable. She can be ruthless in her criticism, applying the rule, “three strikes and you’re out!” A firm believer that life is too short to read mediocre books, if she isn’t grabbed by chapter 3, she puts the book down and moves on. She wants a book to make her life better, she wants to feel excitement at picking it back up again, and burying herself in the characters and moods, twists and turns, of a great story. Her writing reflects this same trait, if her words won’t keep the reader totally engrossed, then she won’t write them.
One of my all-time favourites I’ve read this book 3 times now and, after this review, I’m sure I’ll be tempted to indulge myself for a fourth time. Follett is the master of knife-edge thrillers, if you’ve never read him, start now. Full of treachery and violence, twists and revelations. It’s a scary, but utterly brilliant read.
"Everyone likes a page-turner, and Follett is the best." -The Philadelphia Inquirer
"A hell of a storyteller" (Entertainment Weekly), #1 New York Times bestselling author Ken Follett reinvents the thriller with each new novel. But nothing matches the intricate knife-edge drama of Whiteout. . . .
A missing canister of a deadly virus. A lab technician bleeding from the eyes. Toni Gallo, the security director of a Scottish medical research firm, knows she has problems, but she has no idea of the nightmare to come.
As a Christmas Eve blizzard whips out of the north, several people, Toni among them,…
As a physician, medicine is my job. But along the way, I wondered how medicine got to where it is now–like really wondered. I wondered to the point that I was reading the original treatises written by 18th-century physicians. I started publishing research on medical history and giving presentations at medical conferences. I’d like to think this helps me be a better doctor by broadening my perspective on the healthcare industry. But at the very least, I’ve found these books enjoyable and compelling. I hope you enjoy them, too!
This remarkable story illustrates that if something in healthcare sounds too good to be true, it probably is. I had to stop listening to it before going to sleep because the compelling narrative was keeping me up at night.
The author seamlessly combined this compelling narrative with exceptional research behind the Food and Drug Administration, the heroine who prevented thalidomide approval in the United States, and the catastrophic effects of a pharmaceutical company using loopholes.
Longlisted for the Andrew 2024 Carnegie Medal for Non-Fiction
The shocking, never-before-told story of America's thalidomide victims
In Germany on Christmas Day 1956 a baby girl was born without ears. She was the first victim of the notorious thalidomide epidemic. There would be over 10,000 more across 46 countries.
For years the world believed the United States had avoided the catastrophe. After Frances Kelsey at the Food and Drug Administration became suspicious of the dangers of thalidomide in 1960, she led a successful fight to block its commercial approval.
But now, having probed government and corporate archives and interviewed hundreds…
I am an economist who came to realize that the marketplace of ideas was a political doctrine, and not an empirical description of how we came to know what we think we know. Science has never functioned in the same manner across centuries; it was only during my lifetime that it became recast as a subset of market reality. I have spent a fair amount of effort exploring how economics sought to attain the status of a science; but now the tables have turned. It is now scientists who are trained to become first and foremost market actors, finally elevating the political dominance of the economists.
A best-seller in the UK, it never garnered the attention it deserved in the US. As a trained physician, Goldacre explains why doctors cannot trust the information concerning prescription drugs that is made available to them, and why this should concern every patient. The incentives motivating drug regulators constitute a big part of the problem, but the actual conduct of clinical trials comes in for intensive scrutiny as well. The rigors of double-blinded trials are useless if owners of the data can hide whatever outcomes they don’t like. His chapter on how to bend a clinical trial has become a classic.
"Smart, funny, clear, unflinching: Ben Goldacre is my hero." ―Mary Roach, author of Stiff, Spook, and Bonk
We like to imagine that medicine is based on evidence and the results of fair testing and clinical trials. In reality, those tests and trials are often profoundly flawed. We like to imagine that doctors who write prescriptions for everything from antidepressants to cancer drugs to heart medication are familiar with the research literature about these drugs, when in reality much of the research is hidden from them by drug companies. We like to imagine that doctors are impartially educated, when in reality…
This is one of the most controversial, non-fiction books of 2021, written by a passionate and knowledgeable author. Published during the politically driven COVID pandemic, the author traces with detailed scientific references, the people and organizations involved in what is argued, was the most profound breakdown in public health policy in American and world history. Whether the reader believes the conclusions or not, it is hard to come up with a rebuttal to the citations and conclusions. The author posits that money, power, and hubris drives big pharma, the billionaire, and political elite to make policy and business decisions that are not in the best interests of the general population. Scathing commentary is leveled at household names for their alleged and egregious, decades long, abuses of human populations for personal gain.
If one is interested in another perspective of how the pharmaceutical/medical industry, and the powerful allegedly operate under political…
#1 on AMAZON, and a NEW YORK TIMES, WALL STREET JOURNAL, USA TODAY and PUBLISHERS WEEKLY NATIONAL BOOK BEST SELLERS
Over 1,000,000 copies sold despite censorship, boycotts from bookstores and libraries, and hit pieces against the author.
Pharma-funded mainstream media has convinced millions of Americans that Dr. Anthony Fauci is a hero. Hands down, he is anything but.
As director of the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Anthony Fauci dispenses $6.1 billion in annual taxpayer-provided funding for rigged scientific research, allowing him to dictate the subject, content, and outcome of scientific health research across the globe-truly…
